Glycine Potentiates AMPA Receptor Function through Metabotropic Activation of GluN2A-Containing NMDA Receptors by Li-Jun Li et al.
ORIGINAL RESEARCH
published: 19 October 2016
doi: 10.3389/fnmol.2016.00102
Frontiers in Molecular Neuroscience | www.frontiersin.org 1 October 2016 | Volume 9 | Article 102
Edited by:
Detlev Boison,
Legacy Health, USA
Reviewed by:
John J. Woodward,
Medical University of South Carolina,
USA
Masahito Kawamura,
Jikei University School of Medicine,
Japan
*Correspondence:
Qi Wan
qwanwh@hotmail.com
†
These authors have contributed
equally to this work.
Received: 18 July 2016
Accepted: 29 September 2016
Published: 19 October 2016
Citation:
Li L-J, Hu R, Lujan B, Chen J,
Zhang J-J, Nakano Y, Cui T-Y,
Liao M-X, Chen J-C, Man H-Y, Feng H
and Wan Q (2016) Glycine Potentiates
AMPA Receptor Function through
Metabotropic Activation of
GluN2A-Containing NMDA Receptors.
Front. Mol. Neurosci. 9:102.
doi: 10.3389/fnmol.2016.00102
Glycine Potentiates AMPA Receptor
Function through Metabotropic
Activation of GluN2A-Containing
NMDA Receptors
Li-Jun Li 1 †, Rong Hu 2, 3 †, Brendan Lujan 2, Juan Chen 4, Jian-Jian Zhang 5,
Yasuko Nakano 2, Tian-Yuan Cui 2, Ming-Xia Liao 2, Jin-Cao Chen 5, Heng-Ye Man 6,
Hua Feng 3 and Qi Wan 1, 2, 5, 7*
1Department of Physiology, Toronto Western Research Institute, School of Medicine, University of Toronto, Toronto, Canada,
2Department of Physiology and Cell Biology, University of Nevada School of Medicine, Reno, NV, USA, 3Department of
Neurosurgery, Southwest Hospital, Chongqing, China, 4Department of Neurology, Central Hospital of Wuhan, Wuhan, China,
5Department of Neurosurgery, Zhongnan Hospital, Wuhan University School of Medicine, Wuhan, China, 6Department of
Biology, Boston University, Boston, MA, USA, 7Department of Physiology, School of Basic Medical Sciences, Wuhan
University School of Medicine, Wuhan, China
NMDA receptors are Ca2+-permeable ion channels. The activation of NMDA receptors
requires agonist glutamate and co-agonist glycine. Recent evidence indicates that
NMDA receptor also has metabotropic function. Here we report that in cultured
mouse hippocampal neurons, glycine increases AMPA receptor-mediated currents
independent of the channel activity of NMDA receptors and the activation of glycine
receptors. The potentiation of AMPA receptor function by glycine is antagonized
by the inhibition of ERK1/2. In the hippocampal neurons and in the HEK293 cells
transfected with different combinations of NMDA receptors, glycine preferentially acts
on GluN2A-containing NMDA receptors (GluN2ARs), but not GluN2B-containing NMDA
receptors (GluN2BRs), to enhance ERK1/2 phosphorylation independent of the channel
activity of GluN2ARs. Without requiring the channel activity of GluN2ARs, glycine
increases AMPA receptor-mediated currents through GluN2ARs. Thus, these results
reveal a metabotropic function of GluN2ARs in mediating glycine-induced potentiation
of AMPA receptor function via ERK1/2 activation.
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INTRODUCTION
NMDA receptors (NMDARs) are ligand-gated Ca2+-permeable channels that consist of GluN1,
GluN2 (GluN2A-GluN2D), and GluN3 (GluN3A-GluN3B) subunits (Monyer et al., 1992).
The GluN2A subunit—and GluN2B subunit-containing NMDARs (GluN2ARs and GluN2BRs,
respectively) are the major subtypes of NMDARs expressed in the mammalian CNS (Dingledine
et al., 1999). NMDARs mediate excitatory neurotransmission (Dingledine et al., 1999), which play
essential roles in synaptic plasticity (Malenka and Nicoll, 1999; Barria and Malinow, 2002), neural
development (Constantine-Paton et al., 1990; Kerchner and Nicoll, 2008) and glutamate-induced
neurotoxicity (Choi, 1988; Aarts et al., 2002; Tu et al., 2010). The agonist glutamate binding to
GluN2 subunits and co-agonist glycine binding to GluN1 subunits are required to activate the
Li et al. Metabotropic Activation of GluN2A-Containing NMDA Receptor
channel activity of NMDARs (Johnson and Ascher, 1987).
Different GluN2 subunits confer distinct roles of NMDAR
subtypes (Loftis and Janowsky, 2003; Kim M. J. et al., 2005;
Hayashi et al., 2009). Activation of NMDARs has been shown to
regulate the function of AMPA receptors (AMPARs) (Kim M. J.
et al., 2005), which is considered to be a postsynaptic mechanism
for the regulation of synaptic plasticity including calcium-
dependent long-term potentiation (Malinow and Malenka, 2002;
Collingridge et al., 2004; Li et al., 2010; Man, 2011; Lu and Roche,
2012).
While the ionotropic function of NMDARs has been well
studied, recent studies suggest that NMDAR has a metabotropic
property (Vissel et al., 2001; Kessels et al., 2013; Nabavi et al.,
2013; Tamburri et al., 2013; Birnbaum et al., 2015; Stein et al.,
2015; Weilinger et al., 2016). It is reported that ligand binding
to NMDARs is sufficient to induce long-term depression (LTD);
but does not require ion flow through NMDARs (Nabavi et al.,
2013). NMDA-receptor activation but not ion flux is required
for amyloid-beta induced synaptic depression (Tamburri et al.,
2013) and a metabotropic activity of GluN2BRs mediates β-
amyloid–induced synaptic depression (Kessels et al., 2013). The
metabotropic activity of NMDARs is also found to mediate Abeta
oligomer-induced synaptic loss (Birnbaum et al., 2015), couple
Src family kinases to pannexin-1 in excitotoxic injury (Weilinger
et al., 2016) and drive activity-induced dendritic spine shrinkage
(Stein et al., 2015). In the present study we reveal a metabotropic
activity of GluN2AR that mediates glycine-induced potentiation
of AMPAR function through activation of extracellular signal-
regulated kinase 1/2 (ERK1/2).
MATERIALS AND METHODS
Hippocampal Neuronal Culture
The hippocampal neuronal cultures were prepared from
C57BL/6 mice at gestation day 17 using a modified protocol
(Brewer et al., 1993; Shan et al., 2009). C57BL/6 mice were
obtained from both TorontoWestern Research Institute (TWRI),
University of Nevada School of Medicine (UNSM) and Wuhan
University School of Medicine (WUSM). Briefly, dissociated
neurons were suspended in plating medium (Neurobasal
medium, 2% B-27 supplement, 10% FBS, 0.5 µM L-glutamine,
and 25 µM glutamic acid) and plated on poly-D-lysine coated
Petri dishes. After 3 days in culture, half of the plating
medium was removed and replaced with maintenance medium
(Neurobasal medium, 2% B-27 supplement, and 0.5 µM L-
glutamine). Thereafter, maintenance medium was changed in
the same manner every 3 days. The cultured neurons were
used for all the experiments at 12–14 days after plating. All
animal work was conducted according to the guidelines set
forth by TWRI Canadian Council on Animal Care Committee
(CCACC), the UNSM andWUSM Institutional Animal Care and
Use Committee (IACUC). All procedures were approved by the
TWRI-CCACC, the UNSM–IACUC and WUSM - IACUC.
Electrophysiological Recordings
For the recording of AMPA-induced whole-cell currents, the
recording electrode resistance was 2–5 M′ when filled with a
standard intracellular solution containing 140mM CsCl, 2mM
MgCl2, 1mM CaCl2, 5mM EGTA, 10mM HEPES, 4mM
K2ATP, titrated to pH 7.3 with CsOH and the osmolality
was 300–315 mOsm. Liquid junction potential of 4.8mV was
not corrected. The cultures were bathed in the ECS-1 (10
µM MK-801, 5.0mM EGTA, 5µM strychnine, 0.5µM TTX,
137mM NaCl, 5.4mM KCl, 1.0mM MgCl2, 25mM HEPES,
33mM Glucose, titrated to pH 7.4 with osmolarity of 300–
320 mOsm). Neurons were held at −70mV under voltage-
clamp. AMPAR-mediated whole-cell currents were evoked by
pressure application (22 psi, 100 ms; PDES-2L, npi Electronic
GmbH, Germany) of AMPA (100µM) from a micropipette
with its tip located ∼20µm from the recorded cell. For the
recording of NMDA receptor-mediated whole-cell currents, the
recording electrode resistance was 2–5 M′ when filled with
a standard intracellular solution. Same bath solution was used
without includingMK-801. Neurons were held at+40 mV under
voltage-clamp. NMDA receptor-mediated whole-cell currents
were recorded by pressure application of NMDAR agonist
aspartate (100µM) and glycine (1.0µM; 22 psi, 100 ms) from
a micropipette with its tip located ∼20 µm from the recorded
cell. Drugs were delivered at intervals of 60 s. Data were acquired
with an Axopatch 200B amplifier and pClamp 10 software
interfaced to a Digidata 1322A acquisition board (Molecular
Devices, CA), and signals were filtered at 2 kHz and digitized at
10 kHz.
Recording of miniature EPSCs (mEPSCs) was performed as
described previously (Liu et al., 2006). The cultures were bathed
in the ECS-1 containing 10 µM bicuculline for the recording
of AMPAR mEPSCs. At least 200 individual AMPAR mEPSCs
were collected before and after application of glycine (100µM).
Records were filtered at 2 kHz and analyzed with a Clampfit
10.3 program (Molecular Devices). The other experimental
conditions and methods were same as those of recording for
AMPAR-mediated whole-cell currents.
AMPAR-mediated fEPSPs were recorded in the hemi-
brain slices (400 µm) containing hippocampus prepared by
a vibratome (Leica VT 1200s) using C57BL/6 mice (age of
3∼8 weeks). Before decapitation, mice were anesthetized and
underwent trans-cardiac infusion with a cold choline chloride
solution containing (in mM): 50 NaCl, 80 choline chloride,
3.5 KCl, 7 MgCl2, 0.5 CaCl2, 2 NaH2PO4, 5 HEPES and 20
glucose. Slices were stabilized in oxygenated (95% O2 and 5%
CO2) artificial cerebrospinal fluid (aCSF) containing (in mM):
125 NaCl, 3.5 KCl, 1.25 NaH2PO4, 25 NaHCO3, 2 CaCl2, 1.3
MgCl2, 10 glucose and 2 kynurenic acid (pH 7.4 when aerated
with 95% O2 and 5% CO2) at 35
◦C for 30min. The slices
were then recovered in a modified aCSF (aCSF-1) containing 10
µM bicuculline, 10 µM MK-801 and 5 µM strychnine but no
kynurenic acid at room temperature for over 2 h. All recordings
were performed by perfusing the slices (10–15ml/min) at room
temperature with aCSF-1 that was saturated with 95% O2 and
5% CO2 (Wu et al., 2005). Extracellular recording electrodes
(1∼2 M) filled with aCSF were used for the recording. The
recording electrode was placed in the CA1 apical dendritic
layer. Local afferent stimulation was conducted via placing a
bipolar tungsten wire electrode (tip diameter of 50 µm) in
Frontiers in Molecular Neuroscience | www.frontiersin.org 2 October 2016 | Volume 9 | Article 102
Li et al. Metabotropic Activation of GluN2A-Containing NMDA Receptor
CA3 stratum radiatum. Constant current pulses of 0.1ms were
generated by a Grass stimulator (Grass Technologies, West
Warwick, RI) and delivered through an isolation unit every
30 s. After stable baseline recordings of fEPSPs over 10min
in the slices perfused with aCSF-1, the slices were perfused
with aCSF-1 containing 1mM glycine for 10min, and then
perfused with the aCSF-1 alone for over 30min. MultiClamp
700B (Molecular Devices) was used for the recording. Data
acquisition and analysis were performed using DigiData 1322A
(Molecular Devices) and the analysis software pClamp 10
(Molecular Devices). Signals were filtered at 2 kHz and sampled
at 10 kHz.
Transfections and shRNA Lentiviral
Particles Treatment
The control shRNAs, GluN2A shRNAs or GluN2B shRNAs
were transfected in cultured hippocampal neurons and the
cDNAs of GFP, GluN1, GluN2A, GluN2B GluNR1(N598Q)
were transfected in cultured HEK293 cells. Transfections were
performed using Lipofectamine 2000 (Invitrogen) as previously
described (Wan et al., 1997; Ning et al., 2004).
GluN2A and GluN2B shRNA lentiviral particles were
purchased from GeneChem (China). The transduction of
lentiviral particles was performed in cultured cortical neurons
based on the manufacturer’s instructions.
Western Blotting
Western blotting assay was performed as described previously
(Liu et al., 2006). Antibodies against phospho-ERK1/2
(Thr202/Tyr204) (Cell Signaling Technology, Beverly, MA)
and total ERK1/2 (Cell Signaling Technology) were used.
For the detection of phospho-ERK1/2, samples prepared in
the same day were freshly used for the Western blotting
assay for all the experiments. Primary antibodies were labeled
with horseradish peroxidase-conjugated secondary antibody.
The phospho-ERK1/2 protein bands were imaged using
SuperSignal West Femto Maximum Sensitivity Substrate (Pierce,
Rockford, IL, USA). For the detection of total ERK1/2, the
same polyvinylidene difluoride membrane was stripped and
then reprobed with primary antibody against total ERK1/2 (Cell
Signaling Technology). The ERK1/2 protein bands were imaged
using Pierce ECL Western Blotting Substrate (Pierce). The EC3
Imaging System (UVP, LLC, Upland, CA) was used to obtain
Western blot images directly from polyvinylidene difluoride
membranes. The quantification of Western blots was performed
using ImageJ software as previously described (Ning et al., 2004;
Liu et al., 2006).
Statistics
All population data were expressed as mean ± s.e. Student’s t-
test or ANOVA test was used where appropriate to examine the
statistical significance of the differences between groups of data.
Newman–Keuls tests were used for post-hoc comparisons when
appropriate. Significance was placed at p< 0.05.
RESULTS
Glycine Potentiates AMPA-Induced
Whole-Cell Currents Independent of
NMDAR Channel Activity
To determine whether AMPAR function is regulated by a
metabotropic activity of NMDARs, we measured the effect of
NMDAR co-agonist glycine on AMPAR function in cultured
mouse hippocampal neurons in which the channel activity of
NMDARs was inhibited by a Ca2+-free extracellular solution
(ECS) in which Ca2+ was not included but with the addition
of MK-801 (10 µM), EGTA (5.0mM) and strychnine (10 µM).
This Ca2+-free ECS with the inclusion of MK-801 (a non-
competitive antagonist preventing the flow of ions through the
NMDAR channels) (MacDonald and Nowak, 1990; Rosenmund
et al., 1993) and the Ca2+ chelator EGTA ensured that no
Ca2+ passed through NMDAR channels, The glycine receptor
antagonist strychnine was included in the Ca2+-free ECS to
exclude the possible effects mediated by glycine activation of
glycine receptors (Lynch, 2004). We named this specific solution
as ECS-1 (10 µMMK-801, 5.0mM EGTA, 10 µM strychnine, 0.5
µM TTX, 137mM NaCl, 5.4mM KCl, 1.0mM MgCl2, 25mM
HEPES, 33mM Glucose, titrated to pH 7.4 with osmolarity of
300–320 mOsm). The cultured neurons were treated with ECS-
1 for 10min to suppress the channel activity of NMDARs. This
treatment will be referred to as the NMDAR channel inactivation
procedure.
Prior to recording of AMPA-induced whole-cell currents,
the neuronal cultures were subjected to the NMDAR channel
inactivation procedure. AMPAR currents were recorded in
ECS-1 with the holding potential at −70 mV. Following a
stable recording of AMPAR currents, glycine (100 µM) was
continuously puffed onto the recorded neuron for 1.0min. We
found that the AMPAR peak currents were significantly increased
after the treatment of glycine in a dose-dependent manner
and the currents were inhibited by specific AMPAR antagonist
CNQX (Figures 1A,B). To verify whether the observed effect
of glycine on AMPAR peak currents was under the conditions
where the activity of NMDAR channels was inhibited by the
NMDAR channel inactivation procedure, we measured NMDA-
induced currents and showed that the currents were not evoked
in neurons subjected to NMDAR channel inactivation procedure
(Figure 1C).
To determine whether the observed effect of glycine on
AMPAR currents occurred at physiologically relevant levels
of extracellular Ca2+, we treated the neurons with standard
ECS (137mM NaCl, 2.0mM CaCl2, 5.4mM KCl, 1.0mM
MgCl2, 25mM HEPES, 33mM Glucose, titrated to pH 7.4 with
osmolarity of 300–320 mOsm) containing 10 µM MK-801, 10
µM strychnine and 0.5 µM TTX for 10min. We then recorded
AMPA-induced whole-cell currents and treated the neurons with
glycine (100 µM). As shown in Figure 1D, glycine treatment
for 1.0min increased AMPAR peak currents in the hippocampal
neurons in which NMDAR channels were blocked by MK-801.
Endogenous Mg2+ blocks NMDAR channels while AMPAR
whole-cell currents were recorded at the holding potential of
−70 mV (Kuner and Schoepfer, 1996). To test the glycine effect
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FIGURE 1 | Glycine enhances AMPAR-mediated whole-cell currents in hippocampal neurons in which the NMDAR channel activity and glycine
receptor activation are inhibited. (A) AMPA (100 µM)-induced whole-cell currents are increased by 1.0min treatment of 100 µM glycine in hippocampal neurons
after NMDARs and glycine receptors are inhibited (n = 15, *p < 0.05). The current is reversibly blocked by AMPAR antagonist CNQX (20 µM). (1) Control; (2) Glycine
treatment. (B) The dose-dependent effect of glycine on AMPAR currents (n = 11, *p < 0.05). (C) Sample recordings showing that NMDA-induced whole-cell current
cannot be induced in neurons where NMDAR channels are blocked by MK-801 using our NMDAR blockade procedure. (D) At normal levels of extracellular Ca2+,
glycine (100 µM) increases AMPAR currents independent of the channel activity of NMDARs and the activation of glycine receptors (n = 6, *p < 0.05). (E) Without
treatment with MK-801, AMPAR peak currents are increased by glycine (100 µM) treatment under the holding potential of −70 mV with which the NMDAR channels
are blocked by Mg2+ (n = 7, *p < 0.05). (1) Control; (2) Glycine.
in a physiologically relevant condition in which NMDARs are
not blocked by the external application of ECS-1, we measured
AMPAR currents in neurons treated with standard ECS only
containing 10 µM strychnine and 0.5 µM TTX. We showed that
without use of ECS-1, glycine treatment (100 µM) for 1.0min
increased AMPAR peak currents with the holding potential at
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−70 mV (Figure 1E). Together, these results indicate that glycine
potentiates AMPAR function independent of the channel activity
of NMDARs.
Glycine Enhances AMPAR-Mediated
Synaptic Function Independent of NMDAR
Channel Activity
As the observed enhancement of AMPAR-mediated whole-
cell currents might represent an upregulation of synaptic
responses of AMPARs to glycine, we tested the effect of
glycine on AMPAR-mediated miniature excitatory postsynaptic
currents (mEPSCs). NMDAR channels in the hippocampal
neurons were blocked by the NMDAR channel inactivation
procedure as described above, and the neurons were bathed
in the ECS-1 containing 10 µM GABAA receptor antagonist
bicuculline for the entire recording period. Our data showed
that AMPAR-mediated mEPSCs were significantly increased
in neurons following 1.0min treatment of glycine (100 µM),
and this enhancement lasted for ∼30min (Figure 2A). Glycine
application increased both amplitude and frequency of AMPAR
mEPSCs (Figures 2A–C), suggesting that while glycine enhances
postsynaptic AMPAR function in a NMDAR channel activity-
independent manner, a presynaptic modification is also induced
by glycine.
To validate the observed effect of glycine on synaptic
AMPAR function in more physiologically relevant conditions,
we recorded field excitatory post-synaptic potentials (fEPSP)
in adult mouse hippocampal slices. AMPAR-mediated fEPSPs
were pharmacologically isolated by treating the slices with
GABAA receptor antagonist bicuculline (10 µM) and NMDAR
blocker MK-801(10 µM). As described in the section of
Methods, the NMDAR channels in hippocampal slices were
blocked by a NMDAR channel inactivation procedure that was
similar to that in hippocampal neuronal cultures. After stable
baseline recordings of AMPAR-mediated fEPSPs for over 10min,
treatment of 1.0mM glycine for 10min led to an increased
amplitude of AMPAR-mediated fEPSP in the hippocampus
(Figure 2D).
Potentiation of AMPAR Function by Glycine
Requires ERK1/2 Activation
Because ERK1/2 is involved in mediating AMPAR-mediated
synaptic plasticity (Kim M. J. et al., 2005), we tested the
effect of ERK1/2 inhibition on the upregulation of AMPAR
function by glycine (Hotokezaka et al., 2002). The channels of
NMDARs in hippocampal neurons were blocked by the NMDAR
channel inactivation procedure, and the hippocampal neurons
were bathed in ECS-1 containing ERK1/2 inhibitor U0126 for
the recordings of both AMPAR-mediated mEPSCs and AMPA-
induced whole-cell currents. We found that U0126 treatment for
the entire recording period significantly reduced the upregulation
of both AMPARmEPSC and AMPA-induced whole-cell currents
by glycine (100 µM; 1.0min) (Figures 3A–E), suggesting that
ERK1/2 activation mediates glycine-induced potentiation of
AMPAR function.
Glycine Promotes ERK1/2 Activation
Independent of NMDAR Channel Activity
The electrophysiological results (Figures 1–3) led us to reason
that glycine might activate a metabotropic function of NMDARs
to enhance ERK1/2 activation that in turn lead to the
enhancement of AMPAR function. To test this possibility, we
performed western blot assay to test the effect of glycine on
ERK1/2 activation by measuring the phosphorylation level of
ERK1/2 in cultured hippocampal neurons. The levels of ERK1/2
phosphorylation (p-ERK1/2) on Thr202/Tyr204 were quantified
by calculating the ratio of p-ERK1/2 to total ERK1/2 (t-
ERK1/2). After NMDARs were blocked by the NMDAR channel
inactivation procedure, the cultures were treated with ECS-1
containing glycine (100 µM) for 1.0min and then washed with
ECS-1 for 30min. The neurons were then collected for western
blot assay. As shown in Figure 4A, glycine increased ERK1/2
phosphorylation in hippocampal neurons where the NMDAR
channel activity and glycine receptors were inhibited, and the
glycine effect was dose-dependent (Figure 4B). In the same
experimental conditions, hippocampal neurons were treated with
ECS-1 containing 5.0mM BAPTA, a Ca2+ chelator that has
faster calcium-binding kinetics than EGTA (Adler et al., 1991).
We found that BAPTA treatment did not interfere with glycine
elevation of ERK1/2 phosphorylation (Figure 4C). As BAPTA
chelates the possible residual Ca2+ in the ECS-1, this result
provides further evidence suggesting that the effect of glycine on
ERK1/2 phosphorylation is independent of extracellular Ca2+.
To determine whether the observed effect of glycine on
ERK1/2 phosphorylation occurred at physiologically relevant
levels of extracellular Ca2+, we treated the neurons with standard
ECS containing 10 µM MK-801, 10 µM strychnine and 0.5 µM
TTX for 10min. The neurons were treated with standard ECS
containing 100 µM glycine, 10 µM MK-801, 10 µM strychnine
and 0.5µMTTX for 1.0min and then washed with standard ECS
containing 10 µMMK-801, 10 µM strychnine and 0.5 µMTTX.
We found that at 30min after the treatment of 100 µM glycine,
the levels of ERK1/2 phosphorylation were elevated (Figure 4D).
Glycine Enhances ERK1/2 Activation
through a Metabotropic Activity of
GluN2ARs
In order to obtain direct evidence to determine whether
a metabotropic NMDAR mediated glycine potentiation
of ERK1/2 activation, we tested the effects of glycine on
ERK1/2 phosphorylation in HEK293 cells transiently expressed
NMDARs. The cDNAs of GluN1, GluN2A and/or GluN2B
subunits were transfected in various combinations into the
HEK293 cells (Wan et al., 1997). Prior to the treatment
of glycine (100 µM), the transfected cells were subjected
to the NMDAR channel inactivation procedure. ERK1/2
phosphorylation was measured in the transfected cells at
30min after 1.0min treatment of glycine (100 µM) as
described above (Figure 4A). We found that glycine had
no effect on ERK1/2 phosphorylation in non-transfected
HEK293 cells (Figure 5A). However, glycine increased ERK1/2
phosphorylation in HEK293 cells transfected with cDNAs
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FIGURE 2 | Glycine enhances AMPAR-mediated synaptic currents independent of NMDAR channel activity. (A) Representative AMPAR-mediated mEPSCs
recorded before and 10min after treatment of glycine (100 µM) in hippocampal neurons where NMDARs and glycine receptors are inhibited. (B) Summarized data
showing that mean amplitude of AMPAR mEPSCs is significantly increased after 100 µM glycine treatment (n = 8, *p < 0.05) and that the mean frequency of AMPAR
mEPSCs is also increased after glycine treatment (n = 8, *p < 0.05). (C) Left: sample of averaged AMPAR mEPSCs from the neurons before (995 events) and after
(1407 events) treatment of 100 µM glycine. Middle and Right: cumulative probability plots of peak amplitudes and interevent intervals of AMPAR mEPSCs (bin size 0.5
pA and 10 ms, respectively). The mEPSCs amplitude distribution significantly shifts toward greater values after treatment of 100 µM glycine (p < 0.05). (D) Left:
averaged amplitudes of AMPAR-mediated fEPSP in hippocampal slices recorded before, during and after 1.0mM glycine treatment (n = 12). NMDARs and glycine
receptors in the slices are inhibited before recording. Right: summarized data showing that glycine (1.0mM) increases the amplitudes of AMPAR-mediated fEPSP in
hippocampal slices independent of NMDAR channel activity and glycine receptor activation (n = 12, *p < 0.05 vs. Before).
of GluN1 + GluN2A (Figure 5B) and cDNAs of GluN1 +
GluN2A + GluN2B (Figure 5C), but not in cells transfected
with cDNAs of GluN1 + GluN2B (Figure 5D). We also showed
that glycine did not increase ERK1/2 phosphorylation in
HEK293 cells transfected with cDNAs of GluN1, GluN2A or
GluN2B, respectively (Figure 5E). Thus, glycine preferentially
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FIGURE 3 | Inhibition of ERK1/2 activation prevents potentiation of AMPAR function by glycine. (A) Representative AMPAR mEPSCs recorded before and
10min after 1.0min application of 100 µM glycine in cultured hippocampal neurons in which NMDARs and glycine receptors are inhibited. (B) Summarized data show
that the enhancement of AMPAR mEPSCs by glycine is antagonized by pretreatment of ERK1/2 inhibitor U0126 (5.0 µM; n = 6). (C) Sample of averaged AMPAR
mEPSCs from the neurons at present of U0126 before (881 events) and after (877 events) treatment of 100 µM glycine. (D) Cumulative probability plots of peak
amplitudes and interevent intervals of AMPAR mEPSCs (bin size o.5 pA and 10 ms, respectively). (E) Left: Representative AMPAR whole-cell currents induced by
AMPA (100 µM) recorded before and 10min after treatment of 100 µM glycine in hippocampal neurons where NMDARs and glycine receptors are inhibited. Right:
Summarized data show that the enhancement of AMPAR whole-cell currents by glycine was blocked by U0126 pretreatment (n = 8).
acted on GluN2ARs but not GluN2BRs to enhance ERK1/2
phosphorylation independent of the channel activity of
GluN2ARs, indicating that a metabotropic activity of GluN2ARs
mediates glycine elevation of ERK1/2 phosphorylation. These
data indicate that GluN2A but not GluN2B is required for
synaptic metabotropic NMDARs to mediate the glycine
effect.
N598 is a critical residue at the selectivity filter of NMDAR
channel that determines calcium permeability and GluN1
mutant N598Q has been shown to reduce calcium permeability
(Burnashev et al., 1992). We transfected cDNAs of GluN2A
with GluN1 mutant N598Q in HEK293 cells, and showed
that at 30min after 1.0min treatment of glycine (100 µM)
ERK1/2 phosphorylation in cells co-transfected with GluN2A
and GluN1(N598Q) was increased (Figure 5F). These results
provide molecular evidence to support the conclusion that
GluN2AR-mediated ERK1/2 activation is independent of Ca2+
influx.
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FIGURE 4 | Glycine increases ERK1/2 phosphorylation independent of NMDAR channel activity in hippocampal neurons. (A) Glycine (100 µM) increases
p-ERK1/2 after NMDARs and glycine receptors are inhibited (n = 8, *p < 0.05). (B) Glycine-induced increase of ERK1/2 phosphorylation is dose-dependent in
hippocampal neurons where NMDARs and glycine receptors are inhibited. (C) BAPTA (5.0 mM) treatment does not influence glycine elevation of ERK1/2
phosphorylation in hippocampal neurons where NMDARs and glycine receptors are inhibited (n = 6, *p < 0.05). (D) At normal level of extracellular Ca2+, glycine (100
µM) increases p-ERK1/2 in hippocampal neurons where NMDARs and glycine receptors are inhibited (n = 6, *p < 0.05). Con: Control; Gly: glycine.
We next applied a knockdown approach to validate
the role of metabotropic GluN2ARs in mediating glycine
enhancement of ERK1/2 activation in cultured hippocampal
neurons. The GluN2A protein expression was suppressed in
neurons transducted with GluN2A shRNA lentiviral particles
(Figure 6A). The NMDAR channel inactivation procedure
was used to block NMDAR channels. As expected, ERK1/2
phosphorylation was increased in neurons treated with the
shRNA control at 30min after 1.0min treatment of glycine
(100 µM) (Figure 6B), but the effect of glycine was significantly
reduced in neurons treated with GluN2A shRNA (Figure 6B). In
contrast, glycine increased ERK1/2 phosphorylation in neurons
where GluN2B expression was suppressed by GluN2B shRNA
treatment (Figures 6C,D).
A Metabotropic Activity of GluN2ARs
Mediates Glycine-Induced Potentiation of
AMPAR Function
We thus far showed that glycine-induced potentiation of AMPAR
function required ERK1/2 activation in a NMDAR channel
activity-independent manner, and that a metabotropic activity of
GluN2ARsmediated the elevation of ERK1/2 phosphorylation by
glycine. These results support a possibility that a metabotropic
GluN2AR mediates the potentiation of AMPAR function by
glycine. To test this, we first measured the effect of glycine
on AMPA-induced whole-cell currents in neurons treated with
GFP + GluN2A shRNA. In contrast to neurons treated with
GFP+shRNA control (Figure 7A) or GFP+GluN2B shRNA
(Figure 7B), neurons treated with GFP + GluN2A shRNA
exhibited no significant increase of AMPAR currents at 30min
following 1.0min treatment of glycine (100 µM) (Figure 7C).
We then showed that glycine-induced increase of the amplitude
and frequency of AMPAR mEPSCs was blocked by GluN2A
shRNA transfection (Figure 7D). These data suggest that glycine
activates metabotropic GluN2ARs to enhance AMPAR function.
DISCUSSION
Recent evidence indicates that NMDAR has a metabotropic
property (Vissel et al., 2001; Kessels et al., 2013; Nabavi et al.,
2013; Tamburri et al., 2013; Birnbaum et al., 2015; Stein
et al., 2015; Weilinger et al., 2016). In this study, under the
experimental conditions where the inactivation of NMDARs by
Ca2+-free ECS containing MK-801 or by endogenous Mg2+,
we demonstrate that glycine, through acting on GluN2ARs,
increases AMPAR-mediated synaptic function without
depending on the channel activity of GluN2ARs. In the same
experimental conditions, we show that ERK1/2 is downstream
of GluN2ARs to mediate glycine-induced potentiation of
AMPAR function. Thus, we identify a metabotropic function
of GluN2ARs. It has been recently shown that GluN2BR has a
metabotropic activity that is required for β-amyloid–induced
synaptic depression and sufficient to induce LTD (Nabavi
et al., 2013; Tamburri et al., 2013). Together, these findings
support the conclusion that both GluN2ARs and GluN2BRs have
metabotropic property.
As a co-agonist of NMDARs, glycine is known to notmodulate
the ionotropic function of AMPARs and/or kainite receptors
(Johnson and Ascher, 1987). In this study we demonstrate that
after NMDAR channel activity is suppressed, glycine potentates
AMPAR currents with a threshold concentration of 25 µM
(Figure 1B), which is above the concentration required for
the ionotropic activation of NMDARs (Johnson and Ascher,
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FIGURE 5 | Glycine increases ERK1/2 phosphorylation through metabotropic activity of GluN2ARs in HEK293 cells. (A) The levels of ERK1/2
phosphorylation are not altered by glycine (100 µM) treatment in non-transfected HEK293 cells where NMDARs and glycine receptors are inhibited (n = 6). (B) In
HEK293 cells transfected with GluN1+GluN2A cDNAs, the ERK1/2 phosphorylation is increased by glycine (100 µM) treatment after NMDARs and glycine receptors
are inhibited (n = 6, *p < 0.05). (C) In HEK293 cells transfected with GluN1 + GluN2A + GluN2B cDNAs, the ERK1/2 phosphorylation is increased by glycine (100
µM) treatment after NMDARs and glycine receptors are inhibited (n = 6, *p < 0.05). (D) In HEK293 cells transfected with GluN1 + GluN2B cDNAs, the levels of
ERK1/2 phosphorylation are not altered by glycine (100 µM) treatment after NMDARs and glycine receptors are inhibited (n = 6). (E) In HEK293 cells transfected with
cDNAs of GluN1, GluN2A or GluN2B, respectively, the levels of ERK1/2 phosphorylation are not altered by glycine (100 µM) treatment after NMDARs and glycine
receptors are inhibited (n = 6). (F) In HEK293 cells transfected with GluN1(N598Q) + GluN2A, glycine enhances Erk phosphorylation (n = 6, *P < 0.05 vs. -Gly). Con:
Control; Gly: glycine.
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FIGURE 6 | Glycine increases ERK1/2 phosphorylation via metabotropic activity of GluN2ARs in hippocampal neurons. (A) The GluN2A protein
expression in cultured mouse hippocampal neurons is suppressed by GluN2A shRNA lentiviral particles (n = 5, *p < 0.05). (B) GluN2A knockdown by GluN2A shRNA
blocks glycine-induced increase of p-ERK1/2 in neurons where NMDARs and glycine receptors are inhibited (n = 5, *p < 0.05 vs. shRNA control). (C) The GluN2B
protein expression in mouse hippocampal neurons is suppressed by GluN2B shRNA lentiviral particles (n = 5, *p < 0.05). (D) GluN2B knockdown by GluN2B shRNA
does not block glycine increase of p-ERK1/2 in neurons where NMDARs and glycine receptors are inhibited (n = 5, *p < 0.05 vs. shRNA control; #p < 0.05 vs.
GluN2B shRNA). Gly: glycine.
1987). As GluN2ARs have lower affinity for glycine than
GluN2BRs (Dingledine et al., 1999), it is not unreasonable that
glycine preferentially acts on metabotropic GluN2AsR but not
GluN2BRs to modulate AMPAR currents. These data suggest
a possibility that a new binding site other than the classic
glycine binding site may mediate the effect of glycine on the
metabotropic GluN2ARs. Future study is required to address the
issues.
The physiological relevance of glycine in activating
metabotropic GluN2ARs remains unclear. Since AMPAR plays a
critical role in synaptic plasticity, the observed upregulation of
AMPARs by the glycine activation of metabotropic GluN2ARs
suggests a possible relevance of glycine/metabotropic GluN2ARs
in regulating synaptic transmission. In addition, glycine
is increased in response to ischemia-reperfusion injury
(Globus et al., 1991; Lo et al., 1998). Glycine may act through
metabotropic GluN2ARs to exert its effect in ischemia injury. As
the concentration of glycine to activate metabotropic GluN2ARs
is higher than that of ionotropic NMDARs, the metabotropic
effect of glycine on GluN2ARs might occur when glycine
production and release are increased. Serine is known to be
an endogenous ligand to bind glycine-binding site of NMDA
receptors. It is likely that D-serine may play a similar role to
glycine in triggering the metabotropic activity of GluN2ARs. But
a higher concentration of D-serine may be required for the effect
(Lo et al., 1998).
Our data indicate that while glycine enhances postsynaptic
AMPAR function in a NMDAR channel activity-independent
manner, a presynaptic modification is also induced by glycine.
The underlying mechanism for this presynaptic modification
needs further investigation. However, based on our observation
that knockdown of GluN2A prevents glycine-induced increase
of AMPAR mEPSC frequency, we reason that the presynaptic
modification may be mediated through the metabotropic
GluN2ARs at presynaptic terminals (Berretta and Jones, 1996;
McGuinness et al., 2010; Buchanan et al., 2012).
GluN2ARs and GluN2BRs are shown to play different roles
in regulating neuronal survival/death and synaptic plasticity
(Liu et al., 2004, 2007; Chen et al., 2008). The mechanisms
underlying the differential effects of these NMDAR subtypes have
been elusive. Our study reveals that a metabotropic activity of
GluN2ARs regulates AMPAR function at synaptic sites. This
observation provides a mechanism that may explain in part
why GluN2AR plays a different role than GluN2BR in synaptic
plasticity.
It is not clear how glycine binds to metabotropic GluN2ARs
to activate ERK1/2. One of the possibilities is that a structural
rearrangement of GluN1 and/or GluN2A but not GluN2B
upon glycine binding may directly or indirectly lead to
the activation of ERK1/2-dependent signaling. The ERK1/2
signaling is known to be activated by NMDARs and plays an
important role in synaptic plasticity (Sweatt, 2004; Thomas
and Huganir, 2004). NMDAR-dependent ERK1/2 activation
involves the small GTPase Ras, which is stimulated by specific
nucleotide exchange factors (GEFs) (Thomas and Huganir,
2004). It has been shown that GluN2ARs and GluN2BRs
have antagonistic actions on Ras-ERK1/2 activation (Kim R.
H. et al., 2005). GluN2ARs promote, whereas GluN2BRs
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FIGURE 7 | Glycine enhances AMPAR function through metabotropic activity of GluN2ARs in hippocampal neurons. (A) Transfection of shRNA control
does not influence glycine-induced potentiation of AMPAR currents in hippocampal neurons after NMDARs and glycine receptors are inhibited (n = 7, *p < 0.05). (1)
shRNA control; (2) shRNA control + Gly. (B) GluN2B knockdown by GluN2B shRNA transfection does not influence glycine (100 µM) potentiation of AMPA-induced
whole-cell currents in neurons where NMDARs and glycine receptors are inhibited (n = 7, p < 0.05). (1) GluN2B shRNA; (2) GluN2B shRNA + Glycine. (C)
Knockdown of GluN2A by GluN2A shRNA transfection blocks glycine-induced potentiation of AMPAR currents in hippocampal neurons after NMDARs and glycine
receptors are inhibited (n = 7). (1) GluN2A shRNA; (2) GluN2A shRNA+Gly. (D) Knockdown of GluN2A by GluN2A shRNA prevents glycine-induced increase in mean
amplitude and mean frequency of AMPAR mEPSCs in hippocampal neurons after NMDARs and glycine receptors are inhibited (n = 6 for both all groups). Gly: glycine.
inhibit, Ras-ERK1/2 activation (Kim R. H. et al., 2005).
Through Ras-GRF2 (a Ras-GEF) and ERK1/2 signaling pathway,
GluN2AR induces long-term potentiation (LTP) in CA1
pyramidal neurons of mouse hippocampus (Jin and Feig,
2010). We will determine whether the Ras-GRF2 is involved
in metabotropic GluN2AR-mediated enhancement of ERK1/2
activation.
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